SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Paul Robeson Synthetic CCD — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientPaul Robeson
Date of birth1898-04-09
IdentifiersMRN HR-ML048-SYN-TD; SSN (made up) 000-48-2647
Document date2026-11-01
AuthorTheodore Bankole-Ashworth, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

New patient visit for three months of low mood, exhaustion, poor sleep and withdrawal: depression screening, safety assessment and safety plan, tests for medical causes, and urgent psychiatric consultation. Concerns: He is exhausted, sleeps poorly and has lost the wish to sing, and wants to know what is wrong; He worries that a psychiatric record could be used against him by the people who have taken his passport and his work; He wants to keep working for civil rights and to sing again. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Sertraline 50 mg tablet, one tablet each morning50 mg each morning for two weeksOral route1957-03-12 to 1957-03-25completedS
Sertraline 100 mg tablet, one tablet each morning100 mg each morningOral route1957-03-26 to 1957-04-19completedS
Sertraline 50 mg tablets, three tablets (150 mg) each morning150 mg each morning for two weeksOral route1957-04-20 to 1957-05-03completedS
Sertraline 100 mg tablets, two tablets (200 mg) each morning200 mg each morningOral route1957-05-04 to 1957-06-07completedS
Sertraline 100 mg tablet, one tablet each morning for one week, then stop100 mg each morning for one week during the switchOral route1957-06-08 to 1957-06-14completedS
Venlafaxine extended-release 75 mg capsule, one capsule each morning with food75 mg each morning for one weekOral route1957-06-08 to 1957-06-14completedS
Venlafaxine extended-release 150 mg capsule, one capsule each morning with food150 mg each morning for three weeksOral route1957-06-15 to 1957-07-05completedS
Venlafaxine extended-release 75 mg capsules, three capsules (225 mg) each morning with food225 mg each morning; 30-day supply at a timeOral route1957-07-06activeS
Aripiprazole 2 mg tablet, one tablet each morning2 mg each morning for two weeksOral route1957-08-24 to 1957-09-06completedS
Aripiprazole 5 mg tablet, one tablet each morning5 mg each morningOral route1957-09-07activeS

Procedures

ProcedureDatesStatusEvidence
Advance care planning conversation, about 20 minutes1957-10-05 to 1957-10-05completedS

Immunizations

DateVaccineStatusEvidence
1957-10-05Influenza vaccine, inactivated, trivalent, preservative-freecompletedS
1957-10-05Pneumococcal conjugate vaccine, 20-valent (PCV20)completedS
1957-10-05Zoster vaccine, recombinant, dose 1 of 2completedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1955Prostate surgery; reason not recorded in the cited sourceD (CLM-0008)
1955A breakdown described by his biographer as a period of intense, driven energy followed by a deep depressionD (CLM-0008)

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Health Concerns

ConcernStatusEvidence
He is exhausted, sleeps poorly and has lost the wish to sing, and wants to know what is wrongactiveS
He worries that a psychiatric record could be used against him by the people who have taken his passport and his workactiveS
He wants to keep working for civil rights and to sing againactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 14.2 on 1957-03-09; Leukocytes [#/volume] in Blood by Automated count 6.1 on 1957-03-09; Platelets [#/volume] in Blood by Automated count 240 on 1957-03-09; Sodium [Moles/volume] in Serum or Plasma 136 on 1957-08-24; Potassium [Moles/volume] in Serum or Plasma 4.2 on 1957-03-09; Creatinine [Mass/volume] in Serum or Plasma 1.05 on 1957-03-09; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1952)/1.73 sq M 82 on 1957-03-09; Glucose [Mass/volume] in Serum or Plasma 94 on 1957-08-24; Calcium [Mass/volume] in Serum or Plasma 9.4 on 1957-03-09; Thyrotropin [Units/volume] in Serum or Plasma 1.8 on 1957-03-09; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 420 on 1957-03-09; Folate [Mass/volume] in Serum or Plasma 9.5 on 1957-03-09; Testosterone [Mass/volume] in Serum or Plasma 420 on 1957-03-09; Hemoglobin A1c/Hemoglobin.total in Blood 5.6 on 1957-08-24; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 on 1957-10-05; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 12 on 1957-03-09; Total score [AUDIT-C] 1 on 1957-03-09; Total score [MoCA] 28 on 1957-08-24; Cholesterol [Mass/volume] in Serum or Plasma 204 on 1957-08-24; Cholesterol in HDL [Mass/volume] in Serum or Plasma 46 on 1957-08-24; Triglyceride [Mass/volume] in Serum or Plasma 130 on 1957-08-24; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 132 on 1957-08-24 [S]

Strengths and supports: Supports he names: his music and the spirituals he grew up with, his work for civil rights, and old friends from the stage and the movement [S]

Problems

ProblemClinical statusVerificationCodeProvenance
About three months of low mood, exhaustion, poor sleep with waking at three in the morning, loss of interest in singing and reading, poor appetite with 5 kg weight loss, and withdrawal from friends, in a man of 58 under sustained political pressure; PHQ-9 22 with thoughts of being better off dead; depression suspected; medical causes being excluded and urgent psychiatric consultation arrangedresolvedconfirmed R53.83S — Synthetic presenting problem at intake, superseded by the diagnosis at the psychiatric consultation; anchored to his documented depression and loss of work (D).
Major depressive disorder, recurrent, severe, without psychotic features (second episode; structured diagnostic interview; MDQ negative and no past hypomanic or manic episode on interview)activeconfirmed F33.2S — Synthetic modern diagnosis anchored to his documented depression after the 1955 breakdown (D); the bipolar interpretation (R) is addressed and not adopted.
Sustained political persecution: passport withheld, concerts and recordings cancelled, income lost, and surveillance by federal agencies; a major and realistic stressor, not a delusionactiveconfirmed Z60.5S — Synthetic coding of his documented persecution as a social determinant of his depression.
Acute bronchitis after a cold, without signs of pneumonia; treated without antibiotics and without dextromethorphan or decongestants because of venlafaxine; resolvedresolvedconfirmed J20.9S — Synthetic intercurrent illness; not a historical claim.

Results

DateMeasureValueUnitReference rangeFlagProvenance
1957-03-09Hemoglobin [Mass/volume] in Blood14.2g/dL13.2-17.1 g/dLNormalS
1957-03-09Leukocytes [#/volume] in Blood by Automated count6.110*3/uL4-11 10*3/uLNormalS
1957-03-09Platelets [#/volume] in Blood by Automated count24010*3/uL150-400 10*3/uLNormalS
1957-03-09Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
1957-03-09Potassium [Moles/volume] in Serum or Plasma4.2mmol/L3.5-5.1 mmol/LNormalS
1957-03-09Creatinine [Mass/volume] in Serum or Plasma1.05mg/dL0.7-1.3 mg/dLNormalS
1957-03-09Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1952)/1.73 sq M82mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1957-03-09Glucose [Mass/volume] in Serum or Plasma92mg/dL70-99 mg/dLNormalS
1957-03-09Calcium [Mass/volume] in Serum or Plasma9.4mg/dL8.6-10.3 mg/dLNormalS
1957-03-09Thyrotropin [Units/volume] in Serum or Plasma1.8m[IU]/L0.4-4.5 mIU/LNormalS
1957-03-09Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma420pg/mL232-1245 pg/mLNormalS
1957-03-09Folate [Mass/volume] in Serum or Plasma9.5ng/mL>=3 ng/mLNormalS
1957-03-09Testosterone [Mass/volume] in Serum or Plasma420ng/dL264-916 ng/dLNormalS
1957-03-09Hemoglobin A1c/Hemoglobin.total in Blood5.6%Below 5.7% is normal; 5.7 to 6.4% prediabetesNormalS
1957-03-09Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]22{score}S
1957-03-09Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]12{score}S
1957-03-09Total score [AUDIT-C]1{score}S
1957-03-09Total score [MoCA]28{score}S
1957-04-20Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
1957-04-20Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]19{score}S
1957-06-08Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
1957-06-08Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]17{score}S
1957-08-24Sodium [Moles/volume] in Serum or Plasma136mmol/L135-145 mmol/LNormalS
1957-08-24Glucose [Mass/volume] in Serum or Plasma94mg/dL70-99 mg/dLNormalS
1957-08-24Hemoglobin A1c/Hemoglobin.total in Blood5.6%Below 5.7% is normal; 5.7 to 6.4% prediabetesNormalS
1957-08-24Cholesterol [Mass/volume] in Serum or Plasma204mg/dL<=199 mg/dLHighS
1957-08-24Cholesterol in HDL [Mass/volume] in Serum or Plasma46mg/dL>=40 mg/dLNormalS
1957-08-24Triglyceride [Mass/volume] in Serum or Plasma130mg/dL<=149 mg/dLNormalS
1957-08-24Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation132mg/dL<=129 mg/dLHighS
1957-08-24Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]13{score}S
1957-08-24Total score [MoCA]28{score}S
1957-10-05Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
1957-03-09Body height190cmS
1957-03-09Body weight99kgS
1957-03-09Body mass index (BMI) [Ratio]27.4kg/m2S
1957-03-09Systolic blood pressure128mm[Hg]S
1957-03-09Diastolic blood pressure80mm[Hg]S
1957-03-09Heart rate76/minS
1957-03-09Respiratory rate14/minS
1957-03-09Body temperature36.7CelS
1957-03-09Oxygen saturation in Arterial blood by Pulse oximetry98%S
1957-03-12Body height190cmS
1957-03-12Body weight98.8kgS
1957-03-12Body mass index (BMI) [Ratio]27.4kg/m2S
1957-03-12Systolic blood pressure126mm[Hg]S
1957-03-12Diastolic blood pressure78mm[Hg]S
1957-03-12Heart rate74/minS
1957-03-12Respiratory rate14/minS
1957-03-12Body temperature36.6CelS
1957-03-12Oxygen saturation in Arterial blood by Pulse oximetry98%S
1957-04-20Body height190cmS
1957-04-20Body weight99.5kgS
1957-04-20Body mass index (BMI) [Ratio]27.6kg/m2S
1957-04-20Systolic blood pressure126mm[Hg]S
1957-04-20Diastolic blood pressure78mm[Hg]S
1957-04-20Heart rate72/minS
1957-04-20Respiratory rate14/minS
1957-04-20Body temperature36.7CelS
1957-04-20Oxygen saturation in Arterial blood by Pulse oximetry98%S
1957-06-08Body height190cmS
1957-06-08Body weight100.2kgS
1957-06-08Body mass index (BMI) [Ratio]27.8kg/m2S
1957-06-08Systolic blood pressure128mm[Hg]S
1957-06-08Diastolic blood pressure80mm[Hg]S
1957-06-08Heart rate74/minS
1957-06-08Respiratory rate14/minS
1957-06-08Body temperature36.6CelS
1957-06-08Oxygen saturation in Arterial blood by Pulse oximetry98%S
1957-08-24Body height190cmS
1957-08-24Body weight101kgS
1957-08-24Body mass index (BMI) [Ratio]28kg/m2S
1957-08-24Systolic blood pressure134mm[Hg]S
1957-08-24Diastolic blood pressure84mm[Hg]S
1957-08-24Heart rate78/minS
1957-08-24Respiratory rate14/minS
1957-08-24Body temperature36.6CelS
1957-08-24Oxygen saturation in Arterial blood by Pulse oximetry98%S
1957-07-27Body height190cmS
1957-07-27Body weight100.6kgS
1957-07-27Body mass index (BMI) [Ratio]27.9kg/m2S
1957-07-27Systolic blood pressure132mm[Hg]S
1957-07-27Diastolic blood pressure82mm[Hg]S
1957-07-27Heart rate84/minS
1957-07-27Respiratory rate16/minS
1957-07-27Body temperature37.4CelS
1957-07-27Oxygen saturation in Arterial blood by Pulse oximetry97%S
1957-10-05Body height190cmS
1957-10-05Body weight102.4kgS
1957-10-05Body mass index (BMI) [Ratio]28.4kg/m2S
1957-10-05Systolic blood pressure130mm[Hg]S
1957-10-05Diastolic blood pressure80mm[Hg]S
1957-10-05Heart rate72/minS
1957-10-05Respiratory rate14/minS
1957-10-05Body temperature36.6CelS
1957-10-05Oxygen saturation in Arterial blood by Pulse oximetry98%S

Encounters

DatePurposeStatusProvenance
1957-03-09New patient visit for three months of low mood, exhaustion, poor sleep and withdrawal: depression screening, safety assessment and safety plan, tests for medical causes, and urgent psychiatric consultationfinishedS
1957-03-12Psychiatric consultation and review: diagnosis of recurrent major depression, bipolar screening, start of sertraline and behavioral activationfinishedS
1957-04-20Six-week review: minimal response; sertraline increasedfinishedS
1957-06-08Three-month review: no response to an adequate sertraline trial; switch to venlafaxinefinishedS
1957-08-24Twenty-four-week review: partial response to venlafaxine; treatment-resistant depression; aripiprazole augmentation and an informed consent discussion about ECTfinishedS
1957-07-27Same-day sick visit for acute bronchitis on venlafaxinefinishedS
1957-10-05Periodic adult preventive visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Evaluation: PHQ-9, GAD-7, AUDIT-C and a cognitive screen (MoCA); blood count, metabolic panel, calcium, TSH, vitamin B12, folate, morning testosterone and hemoglobin A1c, with HIV and syphilis tests, to exclude medical causes; a review of medicines; and a sleep apnea screencompletedGL-APA-DEP-2019, GL-VADOD-MDD-2022, GL-CMID-2026S
Urgent psychiatric consultation in three days to confirm the diagnosis with a structured interview, screen for bipolar disorder, judge suicide risk and the level of care, and advise on psychotherapy, medicines, and when ECT or other treatments would be indicatedcompletedGL-APA-DEP-2019, GL-VADOD-MDD-2022, GL-APA-ECT-2001S
Safety: structured suicide-risk assessment, a written safety plan, no firearm in the home, medicines dispensed in limited supplies and kept locked, the 988 Suicide & Crisis Lifeline, and a safety review at every visitcompletedGL-SUICIDE-2024, GL-VADOD-MDD-2022S
Trust and equity: explain who can see his record and how it is protected; a therapist of his choosing, including a Black clinician if he wishes; treat discrimination and persecution as real stressors and record his account of surveillance as realistic; a social worker for help with income and costs; guard against the documented under-treatment of depression in Black patients by measuring response at every visitcompletedGL-WILLIAMS-2007, GL-DISPARITY-2014, GL-SPRENGER-2025, GL-APA-DEP-2019S
Treatment: behavioral activation weekly with a psychologist for about sixteen sessions, then CBT if needed; sertraline 50 mg, raised to 100 mg at two weeks and to 200 mg by eight weeks as tolerated; PHQ-9 at every visit with response defined as a 50 percent fall and remission as a score below 5; sodium at about six weeks; switch to an SNRI if the PHQ-9 falls by less than a quarter after an adequate trial, and consider augmentation, ECT, rTMS or esketamine if a second adequate trial brings only a partial response; watch for hypomania after starting an antidepressantcompletedGL-APA-DEP-2019, GL-VADOD-MDD-2022, GL-CMID-2026S
Switch to venlafaxine extended-release by cross-taper: venlafaxine 75 mg for a week while sertraline is halved, then 150 mg for three weeks and 225 mg; blood pressure at every visit; 30-day supplies because venlafaxine is more dangerous in overdosecompletedGL-VADOD-MDD-2022, GL-APA-DEP-2019S
Treatment-resistant depression: aripiprazole 2 mg, raised to 5 mg at two weeks, with weight at four, eight and twelve weeks, A1c and lipids at baseline and twelve weeks, and an abnormal involuntary movement examination at baseline and six months; an informed consent discussion about ECT (general anesthesia with a muscle relaxant, right unilateral ultrabrief pulse, two or three treatments a week in a defined course, cognitive testing before and during the course, and the right to stop at any time), with rTMS and esketamine as alternatives; ECT not started now and offered if augmentation fails or if he becomes unable to eat or drink, psychotic or acutely suicidalcompletedGL-VADOD-MDD-2022, GL-APA-DEP-2019, GL-APA-ECT-2001, GL-APA-ECT-2024, GL-SPRENGER-2025, GL-CMID-2026S
Acute bronchitis: no antibiotic and no chest X-ray with normal vital signs and a normal chest examination; honey, warm drinks and steam; plain guaifenesin if needed; no dextromethorphan, which with venlafaxine can cause serotonin syndrome, and no pseudoephedrine or phenylephrine, which raise blood pressure further on venlafaxine; check labels of combination cold remedies; return for fever, breathlessness, chest pain or a cough lasting more than three weekscompletedGL-ARTI-2016, GL-VADOD-MDD-2022S
Prevention: stool FIT kit for colorectal screening; the earlier prostate surgery records obtained before any decision on PSA testing; a ten-year cardiovascular risk of about 9 percent discussed, with his choice of diet and activity first and a statin to be reconsidered in a year; hepatitis B and C screening; influenza, PCV20 and the first recombinant zoster dose today, the second zoster dose in two to six monthscompletedGL-USPSTF-CRC-2021, GL-USPSTF-PROS-2018, GL-USPSTF-STATIN-2022, GL-CDC-IMZ-2026S

Goals

GoalTargetStatusOutcomeProvenance
Response to treatment: PHQ-9 down by at least half from 221957-10-05completedPHQ-9 6 at about seven months, a 73 percent fallS
Remission: PHQ-9 below 51957-10-05activeNot yet met: PHQ-9 6 six weeks after augmentation; continuingS
Stay safe: safety plan in place and reviewed at every visit, with no self-harm1957-10-05activeMet so far: no thoughts of suicide since the first months; safety plan reviewed at every visitS
Sing again: daily vocal practice and one public engagement a month1957-10-05completedDaily practice resumed; sang at two community gatherings in the past monthS
Sleep six to seven hours a night1957-10-05completedAbout six and a half hours a nightS

Functional Status

Mental Status

Structured synthetic safety assessment on 1957-03-09: current ideation present, intent absent, plan absent. Outpatient care with a psychiatric consultation in three days and close follow-up. C-SSRS screen: wish to be dead on several days in the past month; no active thoughts of suicide, intent, plan, preparation or past attempt. Risk factors reviewed: severe depression, an older man, insomnia, loss of work and income, isolation, and sustained persecution. Means counseling: there is no firearm in the home and he will not acquire one; medicines will be dispensed in limited supplies and kept in a locked box. A written safety plan was made with him, with warning signs, coping steps, people and places for distraction, and crisis numbers; the 988 Suicide & Crisis Lifeline (call or text 988) was saved in his phone. Safety is reviewed at every visit [S]